Another N-type calcium channel selective ω-conotoxin, CVID, a 28 amino acid peptide with three disulfide bridges, has been isolated from Conus catus. Using Freund's complete adjuvant model of inflammatory pain in rats, chronic intrathecal administration of CVID produced sustained anti-nociception wit...
ω-conotoxin CVIA is a 27 amino acid neuropeptide belonging to a class of four new ω-conotoxins (CVIA-D) extracted from the venom of the Conus Catus snail. These peptides inhibit neuronal voltage sensitive Ca2+ channels in mammals. Interestingly, unlike other ω-conotoxins CVID has a loop...
62-64 The ω-conotoxin CVID (ω-CVID) from Conus catus was shown to target an N-type Ca2+ channel in preganglionic nerve terminals.65 Another peptide, ω-conotoxin TxVII (ω-TxVII), targets the molluscan L-type Ca2+ channels.66 Several ω-conotoxins have been identified and functionally...
Omega-conotoxin CVID had similar potency to omega-conotoxin MVIIA but showed less toxicity in the therapeutic range.Scott DA igpond.net.auWright CEAngus JAEuropean Journal of Pharmacology: An International JournalScott DA, Wright CE, & Angus JA (2002) Actions of intrathecal omega-conotoxins CVID...
In the present study, we examined the potent N-type VGCC antagonist ω-conotoxin CVID and non-selective N- and P/Q-type antagonist CVIB for their ability to block native VGCCs in rat dorsal root ganglion (DRG) neurons and recombinant VGCCs expressed in Xenopus oocytes. ω-Conotoxins CVID...
Leuconotide, a synthetic version of ω-conotoxin CVID (also known as AM336 and CNSB004) has been evaluated in humanclinical trials[78,88]. It is reported to be more effective than ziconotide in non-clinical pain models and demonstrates fewer cardiovascular side effects[83,89]. Recent reports...
Of particular interest are the N-type channel-selective ω-conotoxins GVIA,258 MVIIA,259 and CVID,260 which were isolated from the venoms of the marine snails Conus geographus, Conus magus, and Conus catus, respectively. These ω-conotoxins selectively block ion permeation through N-type Ca2+...
Of further note, CVID has been advanced to human clinical trials where a larger therapeutic window was observed compared with Prialt (Schroeder et al., 2006), however, this peptide did to our knowledge not advance beyond phase II. Nonetheless, the larger therapeutic window has been attributed...
The conotoxin MVIIA, now known as ziconotide, has undergone clinical trials, displaying a significant reduction in pain in a number of different patient populations [18].sThe ω-conotoxin CVID h...Pharmacotherapeutic potential of omegaconotoxin MVIIA (SNX-111), an N-type neuronal calcium channel...
pharmacological targeting properties make ω-conotoxin CVID more N-type specific then ω-conotoxin MVIIA (enclave C,Fig. 2). This has been the impetus for ω-conotoxin CVID's development as a potential drug lead candidate against it's FDA approved competitor ω-conotoxin MVIIA/Prialt®[76–78...